Top

Published in:

01-08-2006 | Original Article

Survivin expression in pre-invasive lesions and non-small cell lung carcinoma

Authors: Nalan Akyürek, Leyla Memiş, Özgür Ekinci, Nurdan Köktürk, Can Öztürk

Published in: Virchows Archiv | Issue 2/2006

Abstract

Survivin is an inhibitor of apoptosis protein, which is overexpressed in many carcinomas, including lung carcinoma. The aim of this immunohistochemical study was to investigate the role of survivin in the early steps of lung carcinogenesis and non-small cell lung carcinomas (NSCLC), and its relationship with expression of p53 protein, a tumor suppressor gene involved in cell cycle control. In the normal bronchial epithelium, low-grade atypical adenomatous hyperplasia (AAH) and non-neoplastic lung parenchyma adjacent to tumor, survivin was found completely negative. Expression of survivin was detected in the areas of squamous metaplasia and dysplasia as well as high-grade AAH lesions adjacent to tumor. Survivin was expressed in 50 (64%) and p53 in 41 (53%) NSCLC. Survivin expression was significantly correlated with lymph node metastasis (p=0.02). There was no correlation between survivin and p53 expression. The patients with expression of survivin had significantly worse prognosis (Log-rank test, p=0.003). Multivariate Cox regression analysis showed TNM stage (p<0.001) and survivin expression (p=0.003) as independent prognostic indicators. In conclusion, survivin expression might be an early step in lung carcinogenesis. Survivin expression might also be used as a prognostic indicator predicting the worse outcome in NSCLC, and might be a novel target for the treatment of patients with preinvasive lesions of lung and NSCLC.

Altieri DC (2003) Validating survivin as a cancer therapeutic target. Nat Rev Cancer 3:46–54PubMedCrossRef

Ambrosini G, Adida C, Altieri DC (1997) A novel anti-apoptosis gene survivin expressed in cancer and lymphoma. Nat Med 3:917–921PubMedCrossRef

Brambilla C, Fievet F, Jeanmart M, de Fraipont F, Lantuejoul S, Frappat V, Ferretti G, Brichon PY, Moro-Sibilot D (2003) Early detection of lung cancer: role of biomarkers. Eur Respir J 39:36s–44sCrossRef

Brundage MD, Davies D, Mackillop WJ (2002) Prognostic factors in non-small cell lung cancer: a decade of progress. Chest 122:1037–1057PubMedCrossRef

Falleni M, Pellegrini C, Marchetti A, Oprandi B, Buttitta F, Barassi F, Santambrogio L, Coggi G, Bosari S (2003) Survivin gene expression in early-stage non-small cell lung cancer. J Pathol 200:620–626PubMedCrossRef

Frost M, Jarboe EA, Orlicky D, Gianani R, Thompson LC, Enomoto T, Shroyer KR (2002) Immunohistochemical localization of survivin in benign cervical mucosa, cervical dysplasia, and invasive squamous cell carcinoma. Am J Clin Pathol 117:738–744PubMedCrossRef

Grossman D, McNiff JM, Li F, Altieri DC (1999) Expression of the apoptosis inhibitor survivin in nonmelanoma skin cancer and gene targeting in a keratinocyte cell line. Lab Invest 79:1121–1126PubMed

Hofmann HS, Simm A, Hammer A, Silber RE, Bartling B (2002) Expression of inhibitors of apoptosis (IAP) proteins in non-small cell human lung cancer. J Cancer Res Clin Oncol 128:554–560PubMedCrossRef

Ichiki Y, Hanagiri T, Takenoyama M, Baba T, Fukuyama T, Nagata Y, Mizukami M, So T, Sugaya M, Yasuda M, So T, Sugio K, Yasumoto K (2005) Tumor specific expression of survivin-2B in lung cancer as a novel target of immunotherapy. Lung Cancer 48:281–289PubMedCrossRef

10.

Ikehara M, Oshita F, Kameda Y, Ito H, Ohgane N, Suzuki R, Saito H, Yamada K, Noda K, Mitsuda A (2002) Expression of survivin correlated with vessel invasion is a marker of poor prognosis in small adenocarcinoma of the lung. Oncol Rep 9:835–838PubMed

11.

Jeanmart M, Lantuejoul S, Fievet F, Moro D, Sturm N, Brambilla C, Brambilla E (2003) Value of immunohistochemical markers in preinvasive bronchial lesions in risk assessment of lung cancer. Clin Cancer Res 9:2195–2203PubMed

12.

Karczmarek-Borowska B, Filip A, Wojcierowski J, Smolen A, Pilecka I, Jablonka A (2005) Survivin antiapoptotic gene expression as a prognostic factor in non-small cell lung cancer: in situ hybridization study. Folia Histochem Cytobiol 43:237–242PubMed

13.

Kawasaki H, Toyoda M, Shinohara H, Okuda J, Watanabe I, Yamamoto T, Tanaka K, Tenjo T, Tanigawa N (2001) Expression of survivin correlates with apoptosis, proliferation, and angiogenesis during human colorectal tumorigenesis. Cancer 91:2026–2032PubMedCrossRef

14.

Kren L, Brazdil J, Hermanova M, Goncharuk VN, Kallakury BV, Kaur P, Ross JS (2004) Prognostic significance of anti-apoptosis proteins survivin and bcl-2 in non-small cell lung carcinomas: a clinicopathologic study of 102 cases. Appl Immunohistochem Mol Morphol 12(1):44–49PubMed

15.

Li F, Yang J, Ramnath N, Javle MM, Tan D (2005) Nuclear or cytoplasmic expression of survivin: what is the significance? Int J Cancer 114(4):509–512PubMedCrossRef

16.

Ling X, Yang J, Tan D, Ramnath N, Younis T, Bundy BN, Slocum HK, Yang L, Zhou M, Li F (2005) Differential expression of survivin-2B and survivin-DeltaEx3 is inversely associated with disease relapse and patient survival in non-small-cell lung cancer (NSCLC). Lung Cancer 49:353–361PubMedCrossRef

17.

Lo Muzio L, Pannone G, Leonardi R, Staibano S, Mignogna MD, De Rosa G, Kudo Y, Takata T, Altieri DC (2003) Survivin a potential early predictor of tumor progression in the oral mucosa. J Dent Res 82:923–928PubMedCrossRef

18.

Lu B, Gonzalez A, Massion PP, Shyr Y, Shaktour B, Carbone DP, Hallahan DE (2004) Nuclear survivin as a biomarker for non-small-cell lung cancer. Br J Cancer 91:537–540PubMedCrossRef

19.

Mirza A, McGuirk M, Hockenberry TN, Wu Q, Ashar H, Black S, Wen SF, Wang L, Kirschmeier P, Bishop WR, Nielsen LL, Pickett CB, Liu S (2002) Human survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway. Oncogene 21:2613–2622PubMedCrossRef

20.

Monzo M, Rosell R, Felip E, Astudillo J, Sanchez JJ, Maestre J, Martin C, Font A, Barnadas A, Abad A (1999) A novel anti-apoptosis gene: re-expression of survivin messenger RNA as a prognosis marker in non-small-cell lung cancers. Clin Oncol 17:2100–2104

21.

Mountain CF (1997) Revisions in the international system for staging lung cancer. Chest 111:1710–1717PubMedCrossRef

22.

Nachmias B, Ashhab Y, Ben-Yehuda D (2004) The inhibitor of apoptosis protein family (IAPs): an emerging therapeutic target in cancer. Semin Cancer Biol 14:231–243PubMedCrossRef

23.

Nakanishi K, Kawai T, Kumaki F, Hiroi S, Mukai M, Ikeda E (2003) Survivin expression in atypical adenomatous hyperplasia of the lung. Am J Clin Pathol 120:712–719PubMedCrossRef

24.

Nakano J, Huang CL, Liu D, Ueno M, Sumitomo S, Yokomise H (2005) Survivin gene expression is negatively regulated by the p53 tumor suppressor gene in non-small cell lung cancer. Int J Oncol 27:1215–1221PubMed

25.

Oshita F, Ito H, Ikehara M, Ohgane N, Hamanaka N, Nakayama H, Saito H, Yamada K, Noda K, Mitsuda A, Kameda Y (2004) Prognostic impact of survivin, cyclin D1, integrin beta1, and VEGF in patients with small adenocarcinoma of stage I lung cancer. Am J Clin Oncol 27:425–428PubMedCrossRef

26.

Rom WN, Hay JG, Lee TC, Jiang Y, Tchou-Wong KM (2000) Molecular and genetic aspects of lung cancer. Am J Respir Crit Care Med 161:1355–1367PubMed

27.

Schimmer AD (2004) Inhibitor of apoptosis proteins: translating basic knowledge into clinical practice. Cancer Res 64:7183–7190PubMedCrossRef

28.

Shinohara ET, Gonzalez A, Massion PP, Chen H, Li M, Freyer AS, Olson SJ, Andersen JJ, Shyr Y, Carbone DP, Johnson DH, Hallahan DE, Lu B (2005) Nuclear survivin predicts recurrence and poor survival in patients with resected nonsmall cell lung carcinoma. Cancer 103:1685–1692PubMedCrossRef

29.

Tanabe H, Yagihashi A, Tsuji N, Shijubo Y, Abe S, Watanabe N (2004) Expression of survivin mRNA and livin mRNA in non-small-cell lung cancer. Lung Cancer 46:299–304PubMedCrossRef

30.

Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC (eds) (2004) World Health Organization classification of tumours. Pathology and genetics of tumours of the lung, Pleura and Heart. IARC, Lyon

31.

Vischioni B, van der Valk P, Span SW, Kruyt FA, Rodriguez JA, Giaccone G (2004) Nuclear localization of survivin is a positive prognostic factor for survival in advanced non-small-cell lung cancer. Ann Oncol 15:1654–1660PubMedCrossRef

32.

Wang XY, Yao Z, Li Y, Liu T, Zheng HY, Zhu CZ, Sun CY, Wang AX, Zhao M, Wu XY (2005) Expression and significance of survivin mRNA in lung cancer tissue microarray detected by FISH. Chin Med Sci J 20:214–216PubMed

Title: Survivin expression in pre-invasive lesions and non-small cell lung carcinoma
Authors: Nalan Akyürek
Leyla Memiş
Özgür Ekinci
Nurdan Köktürk
Can Öztürk
Publication date: 01-08-2006
Publisher: Springer-Verlag
Published in: Virchows Archiv / Issue 2/2006
Print ISSN: 0945-6317
Electronic ISSN: 1432-2307
DOI: https://doi.org/10.1007/s00428-006-0239-9

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Survivin expression in pre-invasive lesions and non-small cell lung carcinoma

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2006

Preinvasive intraductal neoplasia in salivary adenocarcinoma, not otherwise specified

The dilemma of multiorgan donors with high serum PSA—a pathologist’s proposal

Accessible calculation of multirater kappa statistics for pathologists

Nodular glomeruloid pleuroblastoma: a biphasic pleural-based malignant tumor with immature elements

Identity of M2A (D2-40) antigen and gp36 (Aggrus, T1A-2, podoplanin) in human developing testis, testicular carcinoma in situ and germ-cell tumours

Extramedullary hematopoiesis mimicking acute appendicitis: a rare complication of idiopathic myelofibrosis